Our data with selonsertib are consistent with previous studies of mice with global ASK1 deletion subjected to a low dose of Ang II (0.288 mg/[kg·d]) in which cardiac hypertrophy and fibrosis were reduced.31 Our study used a higher hypertensive concentration of Ang II (0.8 mg/[kg·d]),30 resulting in greater fibrosis and hypertrophy and, still, selonsertib was effective at reducing both (Figures 4 and 5). This evidence concerns the gene MAP3K5 and cardiac hypertrophy.